# Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

> **NCT03218384** · PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 20 (actual)

## Conditions studied

- Iron-deficiency

## Interventions

- **DRUG:** Ferric Carboxymaltose
- **DRUG:** Placebo
- **DEVICE:** 31P MRS/MRI

## Key facts

- **NCT ID:** NCT03218384
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-07
- **Primary completion:** 2022-04-04
- **Final completion:** 2022-04-04
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Unable to complete enrollment as planned.
- **Last updated:** 2023-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218384, "Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03218384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*